Using Boceprevir and Telaprevir for the Treatment of Hepatitis C

[Guest guest]

clinical care options

CME/CE-Certified Module

September 21, 2011

A Practical Guide for the Use of Boceprevir and Telaprevir for the

Treatment of Hepatitis C

A panel of experts including Nezam H. Afdhal, MD, FRCPI; Geoffrey M.

Dusheiko, MD, FCP(SA), FRCP; Xavier Forns, MD; Ira M. son, MD; M.

Jensen, MD; Jean-Michel Pawlotsky, MD, PhD; and Fred Poordad, MD; prepared this

practical guide as a consensus recommendation for how telaprevir and boceprevir

should be used in the treatment of patients with HCV infection.

Topics covered include:

Selecting Candidates for Treatment With Telaprevir or Boceprevir in Combination

With PegIFN/RBV

Predictors of Response and Early Viral Kinetics in Patients With HCV

Selecting a Treatment Regimen: Response-Guided Therapy

On-Treatment Management: Futility Rules and Prevention of Resistance

Managing Adverse Effects With Boceprevir- or Telaprevir-Based Therapy

Considerations for Special Patient Populations

The Future of HCV Therapy With the Advent of Direct-Acting Antiviral

Agents

http://clinicaloptions.com/Hepatitis/Treatment%20Updates/HCV%20New%20Agents.aspx

Hepatitis Slide

Library

Review hundreds

of slidesets featuring

the latest hepatitis

treatment data. Then download PowerPoint files for use in your own

noncommercial talks. Click here to start.

HCV

FIND THE ANSWERS AT INPRACTICE.COM

Physicians: Jointly sponsored by the Annenberg Center for Health Sciences

at Eisenhower and Clinical Care Options, LLC.

Nurses: Annenberg Center for Health Sciences is accredited as a provider

of continuing nursing education by the American Nurses Credentialing Center's

Commission on Accreditation.

Pharmacists: The Annenberg Center for Health Sciences at Eisenhower is

accredited by the Accreditation Council for Pharmacy Education as a provider of

continuing pharmacy education.

Release date: September 15, 2011

Expiration date: September 14, 2012

This program is supported by educational grants from Janssen

Therapeutics, Merck, and Vertex.

Topics /font>

Fibrosis and Cirrhosis

HIV Coinfection

HBV

Nash, ALD, etc

HCV

Other Hepatitis Viruses

Hepatocellular Carcinoma

Transplantation

Resources

Live Events

Expert Viewpoints

Bookstore

Slideset Downloads

Interactive Tools

Webcasts

Podcasts

Guidelines

Conference Coverage

CME Programs

Slidesets

Cases

Live Events

Bookstore

Resources

Site Map

RSS

Contact Us

Help

Site Requirements

Terms of Use

Privacy Policy

HIV Site Tour

International Editions

To ensure you receive Clinical Care Options educational materials by

email,

please add info@... to your contacts or address book.

Not

a member yet? Click here |

Unsubscribe from all emails sent from CCO |

Manage email preferences

[Guest guest]

clinical care options

CME/CE-Certified Module

September 21, 2011

A Practical Guide for the Use of Boceprevir and Telaprevir for the

Treatment of Hepatitis C

A panel of experts including Nezam H. Afdhal, MD, FRCPI; Geoffrey M.

Dusheiko, MD, FCP(SA), FRCP; Xavier Forns, MD; Ira M. son, MD; M.

Jensen, MD; Jean-Michel Pawlotsky, MD, PhD; and Fred Poordad, MD; prepared this

practical guide as a consensus recommendation for how telaprevir and boceprevir

should be used in the treatment of patients with HCV infection.

Topics covered include:

Selecting Candidates for Treatment With Telaprevir or Boceprevir in Combination

With PegIFN/RBV

Predictors of Response and Early Viral Kinetics in Patients With HCV

Selecting a Treatment Regimen: Response-Guided Therapy

On-Treatment Management: Futility Rules and Prevention of Resistance

Managing Adverse Effects With Boceprevir- or Telaprevir-Based Therapy

Considerations for Special Patient Populations

The Future of HCV Therapy With the Advent of Direct-Acting Antiviral

Agents

http://clinicaloptions.com/Hepatitis/Treatment%20Updates/HCV%20New%20Agents.aspx

Hepatitis Slide

Library

Review hundreds

of slidesets featuring

the latest hepatitis

treatment data. Then download PowerPoint files for use in your own

noncommercial talks. Click here to start.

HCV

FIND THE ANSWERS AT INPRACTICE.COM

Physicians: Jointly sponsored by the Annenberg Center for Health Sciences

at Eisenhower and Clinical Care Options, LLC.

Nurses: Annenberg Center for Health Sciences is accredited as a provider

of continuing nursing education by the American Nurses Credentialing Center's

Commission on Accreditation.

Pharmacists: The Annenberg Center for Health Sciences at Eisenhower is

accredited by the Accreditation Council for Pharmacy Education as a provider of

continuing pharmacy education.

Release date: September 15, 2011

Expiration date: September 14, 2012

This program is supported by educational grants from Janssen

Therapeutics, Merck, and Vertex.

Topics /font>

Fibrosis and Cirrhosis

HIV Coinfection

HBV

Nash, ALD, etc

HCV

Other Hepatitis Viruses

Hepatocellular Carcinoma

Transplantation

Resources

Live Events

Expert Viewpoints

Bookstore

Slideset Downloads

Interactive Tools

Webcasts

Podcasts

Guidelines

Conference Coverage

CME Programs

Slidesets

Cases

Live Events

Bookstore

Resources

Site Map

RSS

Contact Us

Help

Site Requirements

Terms of Use

Privacy Policy

HIV Site Tour

International Editions

To ensure you receive Clinical Care Options educational materials by

email,

please add info@... to your contacts or address book.

Not

a member yet? Click here |

Unsubscribe from all emails sent from CCO |

Manage email preferences